Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Abrysvo (bivalent RSV vaccine by Year
Abrysvo (bivalent RSV vaccine — maternal & older adults) — U.S. reported YoY (%) (%)
Pfizer Abrysvo (bivalent RSV vaccine: -9.0% in FY2025, up 24.0 pts from a year earlier.
Latest, FY2025
-9.0%
Period ended Dec 31, 2025
Change on a year earlier
+24.0 pts
-33.0% in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
“|| Abrysvo | 1,033 | 755 | 37% | 36% | 542 | 594 | (9%) | 491 | 160 | * | *”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Abrysvo (bivalent RSV vaccine — maternal & older adults) — U.S. reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -9.0% | +24.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | -33.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
Cite this data
StockData. (2026). Pfizer Abrysvo (bivalent RSV vaccine (%), annual FY2024–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/abrysvo-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.